Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
出版年份 2021 全文链接
标题
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
作者
关键词
-
出版物
Lancet Respiratory Medicine
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-06-22
DOI
10.1016/s2213-2600(21)00084-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
- (2020) Lecia V Sequist et al. LANCET ONCOLOGY
- Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
- (2020) Alexander Drilon et al. NATURE MEDICINE
- Frequent Mutations of POT1 Distinguish Pulmonary Sarcomatoid Carcinoma From Other Lung Cancer Histologies
- (2020) Erica Shen et al. Clinical Lung Cancer
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
- (2020) Paul K. Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma
- (2020) Toni K. Choueiri et al. JAMA Oncology
- The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
- (2020) Ravi Salgia et al. CANCER TREATMENT REVIEWS
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
- (2020) Jürgen Wolf et al. NEW ENGLAND JOURNAL OF MEDICINE
- MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
- (2019) Jrhau Lung et al. PLoS One
- The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors
- (2019) Helei Hou et al. Cancer Cell International
- Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring MET exon 14 skipping mutation: a case report
- (2019) Sen Han et al. OncoTargets and Therapy
- Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer
- (2019) M.A. Pruis et al. LUNG CANCER
- Sarcomatoid Carcinoma of the Lung: The Mayo Clinic Experience in 127 Patients
- (2018) Kunlatida Maneenil et al. Clinical Lung Cancer
- Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis
- (2018) Huy Gia Vuong et al. LUNG CANCER
- Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer
- (2018) De-Shen Wang et al. GUT
- Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer
- (2018) Oshin Miranda et al. Cancers
- Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers
- (2017) Alexis B. Cortot et al. JNCI-Journal of the National Cancer Institute
- Pulmonary sarcomatoid carcinoma: University of Cincinnati experience
- (2017) Nagla Abdel Karim et al. Oncotarget
- Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers
- (2017) Alexis B. Cortot et al. JNCI-Journal of the National Cancer Institute
- Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung
- (2016) Mony Ung et al. Clinical Lung Cancer
- Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations
- (2016) Xuewen Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
- (2016) Alexa B. Schrock et al. Journal of Thoracic Oncology
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
- (2015) G. M. Frampton et al. Cancer Discovery
- Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer
- (2014) Hong Jia et al. JOURNAL OF MEDICINAL CHEMISTRY
- Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models
- (2014) Paul R. Gavine et al. Molecular Oncology
- Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma
- (2013) Thibault Vieira et al. Journal of Thoracic Oncology
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now